MK-677 Half-Life: What Pharmacokinetic Studies Report

For laboratory research use only. Not for human consumption. Sold by Explicit SARMs solely as reference material for in-vitro and animal research by qualified professionals. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.

Search for the half-life of MK-677 and you’ll get a confident answer almost everywhere: 4 to 6 hours, or sometimes “24 hours.” Neither figure is easy to trace to human plasma data. That is worth knowing before you design a sampling schedule around one of them.

This page goes through what the indexed literature on ibutamoren (MK-677, MK-0677, L-163,191) does and doesn’t contain on pharmacokinetics, and why the compound’s duration of action and its plasma half-life are two separate questions.

The short answer

We could not find a human plasma elimination half-life for ibutamoren reported in any PubMed-indexed abstract. The 4 to 6 hour figure repeated on reference sites is attributed, where it is attributed at all, to beagle data. The “24 hour” number describes how long GH and IGF-1 stay elevated, which is a pharmacodynamic measure, not how long the parent compound stays in plasma.

What Merck did publish

Merck built a validated assay for the compound early. Constanzer, Chavez-Eng and Matuszewski (J Chromatogr B 1997, PMID 9200526) described an LC-MS/MS method for MK-677 in human plasma with a limit of quantification of 0.1 ng/mL. They monitored the m/z 529 to 267 transition, which matches the protonated free base (MW 528.7). The authors wrote that the method was sensitive enough to map the full pharmacokinetic time course after a single non-injected administration. The PK parameters themselves were not reported in that paper’s abstract.

So the measurement capability existed in 1997. What’s missing from the indexed record is the dataset.

Duration of action in dogs

The best-documented timing data come from beagles. Jacks et al. (Endocrinology 1996, PMID 8940347) gave single gavage and intravenous administrations and tracked serum hormones:

After gavage administration, GH peaked at about 120 minutes and stayed elevated for up to 360 minutes.
IGF-1 was up about 30% at 480 minutes.
After IV administration, GH peaked at 10 minutes and stayed elevated for up to 180 minutes.
Cortisol rose roughly 2.3- to 2.4-fold; LH and prolactin were unchanged.

The authors contrasted this with GHRP-6 and benzolactam secretagogues, which gave shorter GH responses.

Hickey et al. (J Endocrinol 1997, PMID 9071975) then looked at repeat administration over 14 days. Two findings matter for anyone designing a study. First, the GH response fell by 41 to 77% with repeated daily administration, while IGF-1 stayed elevated, up to 126% over control. Second, pre-treatment IGF-1 levels were raised on days 4 to 14 with daily administration but not with alternate-day administration. The authors traced the attenuated GH response to IGF-1 feedback rather than receptor desensitization, because raising IGF-1 with exogenous GH produced the same blunting.

Schleim et al. (Endocrinology 1999, PMID 10098487) showed the IGF-1 and cortisol increases disappear in hypophysectomized dogs, so they depend on an intact pituitary rather than direct action on the liver or adrenal gland.

What the clinical studies measured

Chapman et al. (J Clin Endocrinol Metab 1996, PMID 8954023) sampled blood every 20 minutes for 24 hours in older adults receiving MK-677 once daily. They reported a higher mean 24-hour GH concentration driven by larger GH pulses, without a change in pulse number. That is a careful measurement of GH dynamics. It is not a measurement of ibutamoren in plasma, and it shouldn’t be quoted as a half-life.

The two-year Nass et al. trial (Ann Intern Med 2008, PMID 18981485) likewise reported hormone and body-composition endpoints, not parent-compound kinetics.

Half-life vs duration of effect

These get conflated constantly. Ibutamoren acts on a receptor, GHS-R1a, that amplifies the pituitary’s own pulsatile GH release. Downstream IGF-1 has a long circulating life of its own, largely because it is bound to IGF-binding protein-3. So the hormonal footprint of a single administration can outlast the parent compound by a wide margin. A short plasma half-life and a day-long IGF-1 signal are not contradictory.

For comparison, ipamorelin, a peptide agonist at the same receptor, has a published human terminal half-life of about 2 hours after IV infusion (Gobburu et al., Pharm Res 1999, PMID 10496658), with a single GH episode peaking at 0.67 hours. That is the kind of number you’d want for ibutamoren and can’t find.

Metabolism and detection

Ibutamoren is extensively metabolized. Philip et al. (Rapid Commun Mass Spectrom 2021, PMID 34542924) incubated it with equine liver microsomes and detected 32 metabolites: 20 phase I (mostly hydroxylation) and 12 phase II glucuronides, with no sulfate conjugates. They also saw cleavage of the 2-amino-2-methylpropanamide side chain.

This is why questions like “how long does MK-677 stay in your system” don’t have a clean answer in the literature. Detectability depends on which analyte an assay targets (parent or metabolite), its sensitivity, the matrix and the species. Anti-doping laboratories publish methods for this purpose, and WADA lists ibutamoren under S2.2.4 as prohibited at all times. We aren’t aware of a published, validated detection window for the parent compound.

Practical points for study design

Decide what you are measuring. Parent compound in plasma, GH, and IGF-1 run on very different timescales.
For GH, Merck’s dog data suggest the response window after gavage administration is hours, not a day. Sample densely early.
For IGF-1, account for the feedback attenuation of GH reported by Hickey et al. with repeated administration.
If you are quantifying the compound, use mass spectrometry. Constanzer’s 529 to 267 transition is a published starting point.
Check whether your material is the free base (MW 528.7) or the mesylate (MW 624.8) before calculating molar concentrations.
Use the COA. Ours are available through the contact page.

FAQ

What is the half-life of MK-677?

No human plasma half-life appears in the PubMed-indexed abstracts we reviewed. The widely quoted 4 to 6 hours is attributed to dog data.

Why do some sources say 24 hours?

That figure describes how long GH and IGF-1 stay elevated after once-daily administration, not how long ibutamoren itself remains in plasma.

How long does GH stay elevated in the dog studies?

Up to about 6 hours after a single gavage administration, with IGF-1 still raised at 8 hours (Jacks et al. 1996).

Is MK-677 metabolized?

Extensively. An equine microsome study identified 32 metabolites, mostly hydroxylated forms and glucuronides.

References

Constanzer ML, Chavez-Eng CM, Matuszewski BK. Determination of a novel growth hormone secretagogue (MK-677) in human plasma at picogram levels by LC-APCI-MS/MS. J Chromatogr B. 1997. PubMed 9200526
Jacks T, et al. Endocrinology. 1996. PubMed 8940347
Hickey GJ, et al. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles. J Endocrinol. 1997. PubMed 9071975
Schleim KD, et al. Endocrinology. 1999. PubMed 10098487
Chapman IM, et al. J Clin Endocrinol Metab. 1996. PubMed 8954023
Nass R, et al. Ann Intern Med. 2008. PubMed 18981485
Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers. Pharm Res. 1999. PubMed 10496658
Philip M, et al. Characterization of equine liver microsome-generated metabolites of ibutamoren. Rapid Commun Mass Spectrom. 2021. PubMed 34542924
Patchett AA, et al. Design and biological activities of L-163,191 (MK-0677). Proc Natl Acad Sci U S A. 1995. PubMed 7624358
World Anti-Doping Agency. 2026 Prohibited List. wada-ama.org

Researchers looking at acetylated analogs of ibutamoren can compare MK-777 acetamoren capsules.

MK-677 Half-Life: What the Published Pharmacokinetic Studies Actually Report